{"UserID":{"0":0,"1":1,"2":3,"3":2,"4":0,"5":1,"6":1,"7":3,"8":2,"9":0,"10":1,"11":3,"12":2,"13":0,"14":1,"15":3,"16":2,"17":0,"18":1,"19":3,"20":2,"21":0,"22":1,"23":1,"24":3,"25":2,"26":0,"27":1,"28":3,"29":2,"30":0,"31":1,"32":3,"33":2,"34":0,"35":1,"36":1,"37":3,"38":2,"39":0,"40":1,"41":3,"42":2,"43":0,"44":1,"45":2,"46":3,"47":0,"48":1,"49":2,"50":3,"51":0,"52":1,"53":2,"54":3,"55":0,"56":1,"57":1,"58":2,"59":3,"60":0,"61":1,"62":2,"63":3,"64":0,"65":1,"66":1,"67":2,"68":3,"69":0,"70":1,"71":2,"72":3,"73":0,"74":1,"75":2,"76":3,"77":0,"78":1,"79":1,"80":1,"81":2,"82":3,"83":0,"84":1,"85":2,"86":3,"87":0,"88":1,"89":2,"90":3,"91":0,"92":1,"93":2,"94":3,"95":0,"96":1,"97":2,"98":3,"99":0,"100":1,"101":2,"102":3,"103":0,"104":1,"105":2,"106":3,"107":0,"108":1,"109":2,"110":3,"111":0,"112":1,"113":2,"114":3,"115":0,"116":1,"117":2,"118":3,"119":0,"120":1,"121":2,"122":3,"123":0,"124":1,"125":2,"126":3,"127":0,"128":1,"129":2,"130":3,"131":0,"132":1,"133":2,"134":3,"135":0,"136":1,"137":2,"138":3,"139":0,"140":1,"141":2,"142":3,"143":0,"144":1,"145":2,"146":3,"147":0,"148":1,"149":2,"150":3,"151":0,"152":1,"153":2,"154":3,"155":0,"156":1,"157":1,"158":2,"159":2,"160":3,"161":0,"162":1,"163":1,"164":2,"165":2,"166":3,"167":0,"168":1,"169":2,"170":3,"171":0,"172":1,"173":1,"174":1,"175":2,"176":2,"177":2,"178":3,"179":0,"180":1,"181":2,"182":3,"183":0,"184":1,"185":2,"186":3,"187":0,"188":1,"189":2,"190":2,"191":2,"192":2,"193":3,"194":0,"195":1,"196":2,"197":2,"198":3,"199":0,"200":1,"201":2,"202":2,"203":3,"204":0,"205":1,"206":2,"207":2,"208":3,"209":0,"210":1,"211":2,"212":2,"213":3,"214":0,"215":1,"216":2,"217":3,"218":3,"219":3,"220":0,"221":1,"222":2,"223":3,"224":3,"225":0,"226":1,"227":1,"228":2,"229":3,"230":0,"231":1,"232":2,"233":3,"234":0,"235":1,"236":2,"237":3,"238":0,"239":1,"240":2,"241":3,"242":0,"243":1,"244":2,"245":3,"246":0,"247":1,"248":2,"249":3,"250":0,"251":1,"252":2,"253":3,"254":0,"255":1,"256":2,"257":3,"258":0,"259":1,"260":2,"261":2,"262":2,"263":2,"264":3,"265":0,"266":1,"267":2,"268":2,"269":2,"270":3,"271":0,"272":1,"273":2,"274":2,"275":2,"276":3,"277":0,"278":1,"279":2,"280":2,"281":2,"282":3,"283":0,"284":1,"285":1,"286":2,"287":2,"288":2,"289":2,"290":3,"291":0,"292":1,"293":2,"294":2,"295":2,"296":3,"297":0,"298":1,"299":2,"300":2,"301":2,"302":3,"303":0,"304":1,"305":2,"306":2,"307":2,"308":3,"309":0,"310":1,"311":2,"312":3,"313":0,"314":1,"315":2,"316":3,"317":0,"318":1,"319":2,"320":3,"321":0,"322":1,"323":1,"324":2,"325":2,"326":2,"327":2,"328":3,"329":0,"330":1,"331":2,"332":3,"333":0,"334":1,"335":2,"336":3,"337":0,"338":1,"339":2,"340":3,"341":0,"342":1,"343":2,"344":3,"345":0,"346":1,"347":2,"348":3,"349":0,"350":1,"351":2,"352":2,"353":2,"354":3,"355":0,"356":1,"357":1,"358":2,"359":3,"360":0,"361":1,"362":2,"363":3,"364":0,"365":1,"366":2,"367":3,"368":0,"369":1,"370":2,"371":3,"372":0,"373":1,"374":2,"375":3,"376":0,"377":1,"378":2,"379":3,"380":0,"381":1,"382":2,"383":3,"384":0,"385":1,"386":2,"387":3,"388":0,"389":1,"390":2,"391":3,"392":0,"393":1,"394":2,"395":3,"396":0,"397":1,"398":2,"399":3,"400":0,"401":1,"402":1,"403":2,"404":3,"405":0,"406":1,"407":2,"408":3,"409":0,"410":1,"411":2,"412":3,"413":0,"414":1,"415":2,"416":3,"417":0,"418":1,"419":2,"420":3,"421":0,"422":1,"423":2,"424":3,"425":0,"426":1,"427":2,"428":3},"PromptID":{"0":98,"1":98,"2":98,"3":98,"4":95,"5":95,"6":95,"7":95,"8":95,"9":92,"10":92,"11":92,"12":92,"13":91,"14":91,"15":91,"16":91,"17":90,"18":90,"19":90,"20":90,"21":94,"22":94,"23":94,"24":94,"25":94,"26":99,"27":99,"28":99,"29":99,"30":97,"31":97,"32":97,"33":97,"34":96,"35":96,"36":96,"37":96,"38":96,"39":93,"40":93,"41":93,"42":93,"43":2,"44":2,"45":2,"46":2,"47":3,"48":3,"49":3,"50":3,"51":4,"52":4,"53":4,"54":4,"55":5,"56":5,"57":5,"58":5,"59":5,"60":6,"61":6,"62":6,"63":6,"64":7,"65":7,"66":7,"67":7,"68":7,"69":8,"70":8,"71":8,"72":8,"73":9,"74":9,"75":9,"76":9,"77":10,"78":10,"79":10,"80":10,"81":10,"82":10,"83":11,"84":11,"85":11,"86":11,"87":12,"88":12,"89":12,"90":12,"91":13,"92":13,"93":13,"94":13,"95":14,"96":14,"97":14,"98":14,"99":15,"100":15,"101":15,"102":15,"103":16,"104":16,"105":16,"106":16,"107":20,"108":20,"109":20,"110":20,"111":21,"112":21,"113":21,"114":21,"115":22,"116":22,"117":22,"118":22,"119":23,"120":23,"121":23,"122":23,"123":24,"124":24,"125":24,"126":24,"127":25,"128":25,"129":25,"130":25,"131":26,"132":26,"133":26,"134":26,"135":27,"136":27,"137":27,"138":27,"139":28,"140":28,"141":28,"142":28,"143":29,"144":29,"145":29,"146":29,"147":30,"148":30,"149":30,"150":30,"151":31,"152":31,"153":31,"154":31,"155":33,"156":33,"157":33,"158":33,"159":33,"160":33,"161":34,"162":34,"163":34,"164":34,"165":34,"166":34,"167":35,"168":35,"169":35,"170":35,"171":36,"172":36,"173":36,"174":36,"175":36,"176":36,"177":36,"178":36,"179":37,"180":37,"181":37,"182":37,"183":38,"184":38,"185":38,"186":38,"187":39,"188":39,"189":39,"190":39,"191":39,"192":39,"193":39,"194":40,"195":40,"196":40,"197":40,"198":40,"199":41,"200":41,"201":41,"202":41,"203":41,"204":42,"205":42,"206":42,"207":42,"208":42,"209":43,"210":43,"211":43,"212":43,"213":43,"214":44,"215":44,"216":44,"217":44,"218":44,"219":44,"220":45,"221":45,"222":45,"223":45,"224":45,"225":46,"226":46,"227":46,"228":46,"229":46,"230":47,"231":47,"232":47,"233":47,"234":48,"235":48,"236":48,"237":48,"238":49,"239":49,"240":49,"241":49,"242":50,"243":50,"244":50,"245":50,"246":51,"247":51,"248":51,"249":51,"250":52,"251":52,"252":52,"253":52,"254":53,"255":53,"256":53,"257":53,"258":54,"259":54,"260":54,"261":54,"262":54,"263":54,"264":54,"265":55,"266":55,"267":55,"268":55,"269":55,"270":55,"271":56,"272":56,"273":56,"274":56,"275":56,"276":56,"277":57,"278":57,"279":57,"280":57,"281":57,"282":57,"283":58,"284":58,"285":58,"286":58,"287":58,"288":58,"289":58,"290":58,"291":59,"292":59,"293":59,"294":59,"295":59,"296":59,"297":60,"298":60,"299":60,"300":60,"301":60,"302":60,"303":61,"304":61,"305":61,"306":61,"307":61,"308":61,"309":62,"310":62,"311":62,"312":62,"313":63,"314":63,"315":63,"316":63,"317":64,"318":64,"319":64,"320":64,"321":65,"322":65,"323":65,"324":65,"325":65,"326":65,"327":65,"328":65,"329":66,"330":66,"331":66,"332":66,"333":67,"334":67,"335":67,"336":67,"337":68,"338":68,"339":68,"340":68,"341":69,"342":69,"343":69,"344":69,"345":70,"346":70,"347":70,"348":70,"349":71,"350":71,"351":71,"352":71,"353":71,"354":71,"355":72,"356":72,"357":72,"358":72,"359":72,"360":73,"361":73,"362":73,"363":73,"364":74,"365":74,"366":74,"367":74,"368":75,"369":75,"370":75,"371":75,"372":76,"373":76,"374":76,"375":76,"376":77,"377":77,"378":77,"379":77,"380":78,"381":78,"382":78,"383":78,"384":79,"385":79,"386":79,"387":79,"388":80,"389":80,"390":80,"391":80,"392":81,"393":81,"394":81,"395":81,"396":82,"397":82,"398":82,"399":82,"400":83,"401":83,"402":83,"403":83,"404":83,"405":84,"406":84,"407":84,"408":84,"409":85,"410":85,"411":85,"412":85,"413":86,"414":86,"415":86,"416":86,"417":87,"418":87,"419":87,"420":87,"421":88,"422":88,"423":88,"424":88,"425":89,"426":89,"427":89,"428":89},"PMCID":{"0":2858204,"1":2858204,"2":2858204,"3":2858204,"4":2944158,"5":2944158,"6":2944158,"7":2944158,"8":2944158,"9":2944158,"10":2944158,"11":2944158,"12":2944158,"13":2944158,"14":2944158,"15":2944158,"16":2944158,"17":2944158,"18":2944158,"19":2944158,"20":2944158,"21":2944158,"22":2944158,"23":2944158,"24":2944158,"25":2944158,"26":2871176,"27":2871176,"28":2871176,"29":2871176,"30":2858204,"31":2858204,"32":2858204,"33":2858204,"34":2858204,"35":2858204,"36":2858204,"37":2858204,"38":2858204,"39":2944158,"40":2944158,"41":2944158,"42":2944158,"43":3298351,"44":3298351,"45":3298351,"46":3298351,"47":3298351,"48":3298351,"49":3298351,"50":3298351,"51":3298351,"52":3298351,"53":3298351,"54":3298351,"55":3298351,"56":3298351,"57":3298351,"58":3298351,"59":3298351,"60":3298351,"61":3298351,"62":3298351,"63":3298351,"64":3298351,"65":3298351,"66":3298351,"67":3298351,"68":3298351,"69":3298351,"70":3298351,"71":3298351,"72":3298351,"73":3298351,"74":3298351,"75":3298351,"76":3298351,"77":3298351,"78":3298351,"79":3298351,"80":3298351,"81":3298351,"82":3298351,"83":2366143,"84":2366143,"85":2366143,"86":2366143,"87":2366143,"88":2366143,"89":2366143,"90":2366143,"91":2366143,"92":2366143,"93":2366143,"94":2366143,"95":2366143,"96":2366143,"97":2366143,"98":2366143,"99":2366143,"100":2366143,"101":2366143,"102":2366143,"103":2366143,"104":2366143,"105":2366143,"106":2366143,"107":3233526,"108":3233526,"109":3233526,"110":3233526,"111":3233526,"112":3233526,"113":3233526,"114":3233526,"115":3233526,"116":3233526,"117":3233526,"118":3233526,"119":3233526,"120":3233526,"121":3233526,"122":3233526,"123":3233526,"124":3233526,"125":3233526,"126":3233526,"127":3233526,"128":3233526,"129":3233526,"130":3233526,"131":3233526,"132":3233526,"133":3233526,"134":3233526,"135":3233526,"136":3233526,"137":3233526,"138":3233526,"139":3233526,"140":3233526,"141":3233526,"142":3233526,"143":3233526,"144":3233526,"145":3233526,"146":3233526,"147":3233526,"148":3233526,"149":3233526,"150":3233526,"151":3233526,"152":3233526,"153":3233526,"154":3233526,"155":3233526,"156":3233526,"157":3233526,"158":3233526,"159":3233526,"160":3233526,"161":3233526,"162":3233526,"163":3233526,"164":3233526,"165":3233526,"166":3233526,"167":3233526,"168":3233526,"169":3233526,"170":3233526,"171":3233526,"172":3233526,"173":3233526,"174":3233526,"175":3233526,"176":3233526,"177":3233526,"178":3233526,"179":3233526,"180":3233526,"181":3233526,"182":3233526,"183":2674549,"184":2674549,"185":2674549,"186":2674549,"187":2674549,"188":2674549,"189":2674549,"190":2674549,"191":2674549,"192":2674549,"193":2674549,"194":2674549,"195":2674549,"196":2674549,"197":2674549,"198":2674549,"199":2674549,"200":2674549,"201":2674549,"202":2674549,"203":2674549,"204":2674549,"205":2674549,"206":2674549,"207":2674549,"208":2674549,"209":2674549,"210":2674549,"211":2674549,"212":2674549,"213":2674549,"214":2674549,"215":2674549,"216":2674549,"217":2674549,"218":2674549,"219":2674549,"220":2674549,"221":2674549,"222":2674549,"223":2674549,"224":2674549,"225":2674549,"226":2674549,"227":2674549,"228":2674549,"229":2674549,"230":524504,"231":524504,"232":524504,"233":524504,"234":524504,"235":524504,"236":524504,"237":524504,"238":524504,"239":524504,"240":524504,"241":524504,"242":524504,"243":524504,"244":524504,"245":524504,"246":524504,"247":524504,"248":524504,"249":524504,"250":524504,"251":524504,"252":524504,"253":524504,"254":524504,"255":524504,"256":524504,"257":524504,"258":524504,"259":524504,"260":524504,"261":524504,"262":524504,"263":524504,"264":524504,"265":524504,"266":524504,"267":524504,"268":524504,"269":524504,"270":524504,"271":524504,"272":524504,"273":524504,"274":524504,"275":524504,"276":524504,"277":524504,"278":524504,"279":524504,"280":524504,"281":524504,"282":524504,"283":524504,"284":524504,"285":524504,"286":524504,"287":524504,"288":524504,"289":524504,"290":524504,"291":524504,"292":524504,"293":524504,"294":524504,"295":524504,"296":524504,"297":524504,"298":524504,"299":524504,"300":524504,"301":524504,"302":524504,"303":524504,"304":524504,"305":524504,"306":524504,"307":524504,"308":524504,"309":1764008,"310":1764008,"311":1764008,"312":1764008,"313":1764008,"314":1764008,"315":1764008,"316":1764008,"317":1764008,"318":1764008,"319":1764008,"320":1764008,"321":1764008,"322":1764008,"323":1764008,"324":1764008,"325":1764008,"326":1764008,"327":1764008,"328":1764008,"329":1764008,"330":1764008,"331":1764008,"332":1764008,"333":1764008,"334":1764008,"335":1764008,"336":1764008,"337":1764008,"338":1764008,"339":1764008,"340":1764008,"341":1764008,"342":1764008,"343":1764008,"344":1764008,"345":1764008,"346":1764008,"347":1764008,"348":1764008,"349":1764008,"350":1764008,"351":1764008,"352":1764008,"353":1764008,"354":1764008,"355":1764008,"356":1764008,"357":1764008,"358":1764008,"359":1764008,"360":1764008,"361":1764008,"362":1764008,"363":1764008,"364":3281242,"365":3281242,"366":3281242,"367":3281242,"368":3281242,"369":3281242,"370":3281242,"371":3281242,"372":3281242,"373":3281242,"374":3281242,"375":3281242,"376":3281242,"377":3281242,"378":3281242,"379":3281242,"380":2875419,"381":2875419,"382":2875419,"383":2875419,"384":2875419,"385":2875419,"386":2875419,"387":2875419,"388":2875419,"389":2875419,"390":2875419,"391":2875419,"392":2875419,"393":2875419,"394":2875419,"395":2875419,"396":2875419,"397":2875419,"398":2875419,"399":2875419,"400":2875419,"401":2875419,"402":2875419,"403":2875419,"404":2875419,"405":2875419,"406":2875419,"407":2875419,"408":2875419,"409":2944158,"410":2944158,"411":2944158,"412":2944158,"413":2944158,"414":2944158,"415":2944158,"416":2944158,"417":2944158,"418":2944158,"419":2944158,"420":2944158,"421":2944158,"422":2944158,"423":2944158,"424":2944158,"425":2944158,"426":2944158,"427":2944158,"428":2944158},"Valid Label":{"0":true,"1":true,"2":true,"3":true,"4":true,"5":true,"6":true,"7":true,"8":true,"9":true,"10":true,"11":true,"12":true,"13":true,"14":true,"15":true,"16":true,"17":true,"18":true,"19":true,"20":true,"21":true,"22":true,"23":true,"24":true,"25":true,"26":true,"27":true,"28":true,"29":true,"30":true,"31":true,"32":true,"33":true,"34":true,"35":true,"36":true,"37":true,"38":true,"39":true,"40":true,"41":true,"42":true,"43":true,"44":true,"45":true,"46":true,"47":true,"48":true,"49":true,"50":false,"51":true,"52":true,"53":true,"54":true,"55":true,"56":true,"57":true,"58":true,"59":false,"60":true,"61":true,"62":true,"63":true,"64":true,"65":true,"66":true,"67":true,"68":true,"69":true,"70":true,"71":true,"72":true,"73":true,"74":true,"75":true,"76":true,"77":true,"78":false,"79":false,"80":false,"81":true,"82":false,"83":true,"84":true,"85":true,"86":true,"87":true,"88":true,"89":true,"90":true,"91":true,"92":true,"93":true,"94":true,"95":true,"96":true,"97":true,"98":true,"99":true,"100":true,"101":true,"102":true,"103":true,"104":true,"105":false,"106":false,"107":true,"108":true,"109":true,"110":true,"111":true,"112":true,"113":true,"114":true,"115":true,"116":true,"117":true,"118":true,"119":true,"120":true,"121":true,"122":true,"123":true,"124":true,"125":true,"126":true,"127":true,"128":true,"129":true,"130":true,"131":true,"132":true,"133":true,"134":true,"135":true,"136":true,"137":true,"138":true,"139":true,"140":true,"141":false,"142":true,"143":true,"144":true,"145":false,"146":false,"147":true,"148":true,"149":false,"150":false,"151":true,"152":false,"153":false,"154":false,"155":true,"156":true,"157":true,"158":true,"159":true,"160":true,"161":true,"162":true,"163":true,"164":true,"165":true,"166":true,"167":true,"168":true,"169":true,"170":true,"171":true,"172":true,"173":true,"174":true,"175":true,"176":true,"177":true,"178":true,"179":true,"180":true,"181":true,"182":true,"183":true,"184":true,"185":true,"186":true,"187":true,"188":true,"189":true,"190":true,"191":true,"192":true,"193":true,"194":true,"195":true,"196":true,"197":true,"198":true,"199":true,"200":true,"201":true,"202":true,"203":true,"204":true,"205":true,"206":true,"207":true,"208":true,"209":true,"210":true,"211":true,"212":true,"213":true,"214":true,"215":false,"216":false,"217":true,"218":true,"219":true,"220":true,"221":false,"222":false,"223":true,"224":true,"225":true,"226":false,"227":false,"228":false,"229":false,"230":true,"231":true,"232":true,"233":true,"234":true,"235":true,"236":true,"237":true,"238":true,"239":true,"240":true,"241":true,"242":true,"243":true,"244":true,"245":true,"246":true,"247":true,"248":true,"249":true,"250":true,"251":true,"252":true,"253":true,"254":true,"255":true,"256":true,"257":true,"258":true,"259":true,"260":true,"261":true,"262":true,"263":true,"264":true,"265":true,"266":true,"267":true,"268":true,"269":true,"270":true,"271":true,"272":true,"273":true,"274":true,"275":true,"276":true,"277":true,"278":true,"279":true,"280":true,"281":true,"282":true,"283":true,"284":true,"285":true,"286":true,"287":true,"288":true,"289":true,"290":true,"291":true,"292":true,"293":true,"294":true,"295":true,"296":true,"297":true,"298":true,"299":true,"300":true,"301":true,"302":true,"303":true,"304":true,"305":true,"306":true,"307":true,"308":true,"309":true,"310":true,"311":true,"312":true,"313":true,"314":true,"315":true,"316":true,"317":true,"318":true,"319":true,"320":true,"321":true,"322":true,"323":true,"324":true,"325":true,"326":true,"327":true,"328":true,"329":true,"330":true,"331":false,"332":true,"333":true,"334":false,"335":true,"336":true,"337":true,"338":true,"339":true,"340":false,"341":true,"342":true,"343":true,"344":true,"345":true,"346":true,"347":true,"348":true,"349":true,"350":true,"351":true,"352":true,"353":true,"354":true,"355":true,"356":true,"357":true,"358":true,"359":true,"360":true,"361":true,"362":true,"363":true,"364":true,"365":true,"366":true,"367":true,"368":true,"369":true,"370":true,"371":true,"372":true,"373":true,"374":true,"375":true,"376":true,"377":false,"378":true,"379":false,"380":true,"381":true,"382":true,"383":true,"384":true,"385":true,"386":true,"387":true,"388":true,"389":true,"390":true,"391":true,"392":true,"393":true,"394":true,"395":true,"396":true,"397":true,"398":true,"399":true,"400":true,"401":true,"402":true,"403":true,"404":true,"405":true,"406":true,"407":false,"408":false,"409":true,"410":true,"411":true,"412":true,"413":true,"414":true,"415":true,"416":true,"417":true,"418":true,"419":true,"420":true,"421":true,"422":true,"423":true,"424":true,"425":true,"426":true,"427":true,"428":true},"Valid Reasoning":{"0":true,"1":true,"2":true,"3":true,"4":true,"5":true,"6":true,"7":true,"8":true,"9":true,"10":true,"11":true,"12":true,"13":false,"14":true,"15":false,"16":true,"17":true,"18":true,"19":true,"20":true,"21":true,"22":true,"23":true,"24":false,"25":true,"26":true,"27":true,"28":true,"29":true,"30":true,"31":true,"32":true,"33":true,"34":true,"35":true,"36":true,"37":true,"38":true,"39":true,"40":true,"41":false,"42":true,"43":true,"44":true,"45":true,"46":true,"47":true,"48":true,"49":true,"50":false,"51":true,"52":true,"53":true,"54":true,"55":true,"56":true,"57":true,"58":true,"59":false,"60":true,"61":true,"62":true,"63":true,"64":true,"65":true,"66":true,"67":true,"68":true,"69":true,"70":true,"71":true,"72":true,"73":true,"74":true,"75":true,"76":true,"77":true,"78":false,"79":false,"80":false,"81":true,"82":false,"83":true,"84":true,"85":true,"86":true,"87":true,"88":true,"89":true,"90":true,"91":true,"92":true,"93":true,"94":true,"95":true,"96":true,"97":true,"98":true,"99":true,"100":true,"101":true,"102":true,"103":true,"104":true,"105":false,"106":false,"107":true,"108":true,"109":true,"110":true,"111":true,"112":true,"113":true,"114":true,"115":true,"116":true,"117":true,"118":true,"119":true,"120":true,"121":true,"122":true,"123":true,"124":true,"125":true,"126":true,"127":true,"128":true,"129":true,"130":true,"131":true,"132":true,"133":true,"134":true,"135":true,"136":true,"137":true,"138":true,"139":true,"140":true,"141":false,"142":true,"143":true,"144":true,"145":false,"146":false,"147":true,"148":true,"149":false,"150":false,"151":true,"152":false,"153":false,"154":false,"155":true,"156":true,"157":true,"158":true,"159":true,"160":true,"161":true,"162":true,"163":true,"164":true,"165":true,"166":true,"167":true,"168":true,"169":true,"170":true,"171":true,"172":true,"173":true,"174":true,"175":true,"176":true,"177":true,"178":true,"179":true,"180":true,"181":true,"182":true,"183":true,"184":true,"185":true,"186":true,"187":true,"188":true,"189":true,"190":true,"191":true,"192":true,"193":true,"194":true,"195":true,"196":true,"197":true,"198":true,"199":true,"200":true,"201":true,"202":true,"203":true,"204":true,"205":true,"206":true,"207":true,"208":true,"209":true,"210":true,"211":true,"212":true,"213":true,"214":true,"215":false,"216":false,"217":true,"218":true,"219":true,"220":true,"221":false,"222":false,"223":true,"224":true,"225":true,"226":false,"227":false,"228":false,"229":false,"230":true,"231":true,"232":true,"233":true,"234":true,"235":true,"236":true,"237":true,"238":true,"239":true,"240":true,"241":true,"242":true,"243":true,"244":true,"245":true,"246":true,"247":true,"248":true,"249":true,"250":true,"251":true,"252":true,"253":true,"254":true,"255":true,"256":true,"257":true,"258":true,"259":true,"260":true,"261":true,"262":true,"263":true,"264":true,"265":true,"266":true,"267":true,"268":true,"269":true,"270":true,"271":true,"272":true,"273":true,"274":true,"275":true,"276":true,"277":true,"278":true,"279":true,"280":true,"281":true,"282":true,"283":true,"284":true,"285":true,"286":true,"287":true,"288":true,"289":true,"290":true,"291":true,"292":true,"293":true,"294":true,"295":true,"296":true,"297":true,"298":true,"299":true,"300":true,"301":true,"302":true,"303":true,"304":true,"305":true,"306":true,"307":true,"308":true,"309":true,"310":true,"311":true,"312":true,"313":true,"314":true,"315":true,"316":true,"317":true,"318":true,"319":true,"320":true,"321":true,"322":true,"323":true,"324":true,"325":true,"326":true,"327":true,"328":true,"329":true,"330":true,"331":false,"332":true,"333":true,"334":false,"335":true,"336":true,"337":true,"338":true,"339":true,"340":false,"341":true,"342":true,"343":true,"344":true,"345":true,"346":true,"347":true,"348":true,"349":true,"350":true,"351":true,"352":true,"353":true,"354":true,"355":true,"356":true,"357":true,"358":true,"359":true,"360":true,"361":true,"362":true,"363":true,"364":true,"365":true,"366":true,"367":true,"368":true,"369":true,"370":true,"371":true,"372":true,"373":true,"374":true,"375":true,"376":true,"377":false,"378":true,"379":false,"380":true,"381":true,"382":true,"383":true,"384":true,"385":true,"386":true,"387":true,"388":true,"389":true,"390":true,"391":true,"392":true,"393":true,"394":true,"395":true,"396":true,"397":true,"398":true,"399":true,"400":true,"401":true,"402":true,"403":true,"404":true,"405":true,"406":true,"407":false,"408":false,"409":true,"410":true,"411":true,"412":true,"413":true,"414":true,"415":true,"416":true,"417":true,"418":true,"419":true,"420":true,"421":true,"422":true,"423":true,"424":true,"425":true,"426":true,"427":true,"428":true},"Label":{"0":"significantly increased","1":"significantly increased","2":"significantly increased","3":"significantly increased","4":"significantly increased","5":"significantly increased","6":"significantly increased","7":"significantly increased","8":"significantly increased","9":"no significant difference","10":"no significant difference","11":"no significant difference","12":"no significant difference","13":"no significant difference","14":"no significant difference","15":"no significant difference","16":"no significant difference","17":"significantly increased","18":"significantly increased","19":"significantly increased","20":"significantly increased","21":"no significant difference","22":"no significant difference","23":"no significant difference","24":"no significant difference","25":"no significant difference","26":"significantly decreased","27":"significantly decreased","28":"significantly decreased","29":"significantly decreased","30":"no significant difference","31":"no significant difference","32":"no significant difference","33":"no significant difference","34":"significantly increased","35":"significantly increased","36":"significantly increased","37":"significantly increased","38":"significantly increased","39":"no significant difference","40":"no significant difference","41":"no significant difference","42":"no significant difference","43":"no significant difference","44":"no significant difference","45":"no significant difference","46":"no significant difference","47":"significantly increased","48":"significantly increased","49":"significantly increased","50":"invalid prompt","51":"no significant difference","52":"no significant difference","53":"no significant difference","54":"no significant difference","55":"no significant difference","56":"no significant difference","57":"no significant difference","58":"no significant difference","59":"significantly increased","60":"no significant difference","61":"no significant difference","62":"no significant difference","63":"no significant difference","64":"no significant difference","65":"no significant difference","66":"no significant difference","67":"no significant difference","68":"no significant difference","69":"no significant difference","70":"no significant difference","71":"no significant difference","72":"no significant difference","73":"significantly increased","74":"significantly increased","75":"significantly increased","76":"significantly increased","77":"significantly increased","78":"no significant difference","79":"no significant difference","80":"no significant difference","81":"significantly increased","82":"no significant difference","83":"no significant difference","84":"no significant difference","85":"no significant difference","86":"no significant difference","87":"no significant difference","88":"no significant difference","89":"no significant difference","90":"no significant difference","91":"no significant difference","92":"no significant difference","93":"no significant difference","94":"no significant difference","95":"significantly decreased","96":"significantly decreased","97":"significantly decreased","98":"significantly decreased","99":"no significant difference","100":"no significant difference","101":"no significant difference","102":"no significant difference","103":"no significant difference","104":"no significant difference","105":"invalid prompt","106":"invalid prompt","107":"no significant difference","108":"no significant difference","109":"no significant difference","110":"no significant difference","111":"no significant difference","112":"no significant difference","113":"no significant difference","114":"no significant difference","115":"no significant difference","116":"no significant difference","117":"no significant difference","118":"no significant difference","119":"no significant difference","120":"no significant difference","121":"no significant difference","122":"no significant difference","123":"no significant difference","124":"no significant difference","125":"no significant difference","126":"no significant difference","127":"no significant difference","128":"no significant difference","129":"no significant difference","130":"no significant difference","131":"no significant difference","132":"no significant difference","133":"no significant difference","134":"no significant difference","135":"no significant difference","136":"no significant difference","137":"no significant difference","138":"no significant difference","139":"no significant difference","140":"no significant difference","141":"invalid prompt","142":"no significant difference","143":"no significant difference","144":"no significant difference","145":"invalid prompt","146":"invalid prompt","147":"no significant difference","148":"no significant difference","149":"invalid prompt","150":"invalid prompt","151":"significantly decreased","152":"no significant difference","153":"no significant difference","154":"no significant difference","155":"significantly increased","156":"significantly increased","157":"significantly increased","158":"significantly increased","159":"significantly increased","160":"significantly increased","161":"significantly increased","162":"significantly increased","163":"significantly increased","164":"significantly increased","165":"significantly increased","166":"significantly increased","167":"no significant difference","168":"no significant difference","169":"no significant difference","170":"no significant difference","171":"no significant difference","172":"no significant difference","173":"no significant difference","174":"no significant difference","175":"no significant difference","176":"no significant difference","177":"no significant difference","178":"no significant difference","179":"no significant difference","180":"no significant difference","181":"no significant difference","182":"no significant difference","183":"significantly decreased","184":"significantly decreased","185":"significantly decreased","186":"significantly decreased","187":"significantly increased","188":"significantly increased","189":"significantly increased","190":"significantly increased","191":"significantly increased","192":"significantly increased","193":"significantly increased","194":"no significant difference","195":"no significant difference","196":"no significant difference","197":"no significant difference","198":"no significant difference","199":"no significant difference","200":"no significant difference","201":"no significant difference","202":"no significant difference","203":"no significant difference","204":"significantly increased","205":"significantly increased","206":"significantly increased","207":"significantly increased","208":"significantly increased","209":"significantly increased","210":"significantly increased","211":"significantly increased","212":"significantly increased","213":"significantly increased","214":"significantly increased","215":"no significant difference","216":"no significant difference","217":"significantly increased","218":"significantly increased","219":"significantly increased","220":"significantly increased","221":"no significant difference","222":"no significant difference","223":"significantly increased","224":"significantly increased","225":"significantly increased","226":"no significant difference","227":"no significant difference","228":"no significant difference","229":"no significant difference","230":"significantly decreased","231":"significantly decreased","232":"significantly decreased","233":"significantly decreased","234":"significantly increased","235":"significantly increased","236":"significantly increased","237":"significantly increased","238":"significantly increased","239":"significantly increased","240":"significantly increased","241":"significantly increased","242":"significantly increased","243":"significantly increased","244":"significantly increased","245":"significantly increased","246":"significantly decreased","247":"significantly decreased","248":"significantly decreased","249":"significantly decreased","250":"no significant difference","251":"no significant difference","252":"no significant difference","253":"no significant difference","254":"no significant difference","255":"no significant difference","256":"no significant difference","257":"no significant difference","258":"significantly increased","259":"significantly increased","260":"significantly increased","261":"significantly increased","262":"significantly increased","263":"significantly increased","264":"significantly increased","265":"no significant difference","266":"no significant difference","267":"no significant difference","268":"no significant difference","269":"no significant difference","270":"no significant difference","271":"no significant difference","272":"no significant difference","273":"no significant difference","274":"no significant difference","275":"no significant difference","276":"no significant difference","277":"no significant difference","278":"no significant difference","279":"no significant difference","280":"no significant difference","281":"no significant difference","282":"no significant difference","283":"no significant difference","284":"no significant difference","285":"no significant difference","286":"no significant difference","287":"no significant difference","288":"no significant difference","289":"no significant difference","290":"no significant difference","291":"no significant difference","292":"no significant difference","293":"no significant difference","294":"no significant difference","295":"no significant difference","296":"no significant difference","297":"no significant difference","298":"no significant difference","299":"no significant difference","300":"no significant difference","301":"no significant difference","302":"no significant difference","303":"no significant difference","304":"no significant difference","305":"no significant difference","306":"no significant difference","307":"no significant difference","308":"no significant difference","309":"no significant difference","310":"no significant difference","311":"no significant difference","312":"no significant difference","313":"no significant difference","314":"no significant difference","315":"no significant difference","316":"no significant difference","317":"no significant difference","318":"no significant difference","319":"no significant difference","320":"no significant difference","321":"no significant difference","322":"no significant difference","323":"no significant difference","324":"no significant difference","325":"no significant difference","326":"no significant difference","327":"no significant difference","328":"no significant difference","329":"no significant difference","330":"no significant difference","331":"invalid prompt","332":"no significant difference","333":"significantly decreased","334":"no significant difference","335":"significantly decreased","336":"significantly decreased","337":"significantly decreased","338":"significantly decreased","339":"significantly decreased","340":"significantly increased","341":"significantly increased","342":"significantly increased","343":"significantly increased","344":"significantly increased","345":"no significant difference","346":"no significant difference","347":"no significant difference","348":"no significant difference","349":"no significant difference","350":"no significant difference","351":"no significant difference","352":"no significant difference","353":"no significant difference","354":"no significant difference","355":"no significant difference","356":"no significant difference","357":"no significant difference","358":"no significant difference","359":"no significant difference","360":"no significant difference","361":"no significant difference","362":"no significant difference","363":"no significant difference","364":"significantly increased","365":"significantly increased","366":"significantly increased","367":"significantly increased","368":"significantly increased","369":"significantly increased","370":"significantly increased","371":"significantly increased","372":"no significant difference","373":"no significant difference","374":"no significant difference","375":"no significant difference","376":"significantly decreased","377":"significantly increased","378":"significantly decreased","379":"significantly increased","380":"no significant difference","381":"no significant difference","382":"no significant difference","383":"no significant difference","384":"no significant difference","385":"no significant difference","386":"no significant difference","387":"no significant difference","388":"significantly increased","389":"significantly increased","390":"significantly increased","391":"significantly increased","392":"no significant difference","393":"no significant difference","394":"no significant difference","395":"no significant difference","396":"significantly increased","397":"significantly increased","398":"significantly increased","399":"significantly increased","400":"significantly decreased","401":"significantly decreased","402":"significantly decreased","403":"significantly decreased","404":"significantly decreased","405":"significantly decreased","406":"significantly decreased","407":"invalid prompt","408":"significantly increased","409":"no significant difference","410":"no significant difference","411":"no significant difference","412":"no significant difference","413":"no significant difference","414":"no significant difference","415":"no significant difference","416":"no significant difference","417":"no significant difference","418":"no significant difference","419":"no significant difference","420":"no significant difference","421":"no significant difference","422":"no significant difference","423":"no significant difference","424":"no significant difference","425":"significantly increased","426":"significantly increased","427":"significantly increased","428":"significantly increased"},"Annotations":{"0":"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037)","1":"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037).","2":"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037).","3":"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037).","4":"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).","5":"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).","6":"The maximum IVD dwell time was 1,023 hours (43 days) in the clinical replacement group, and this cannula was still working well on removal for completion of therapy.","7":"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).","8":"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).","9":"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)","10":"There were no local infections or IVD-related bloodstream infections in either group.","11":"Phlebitis, n (%)\t12 (7%)\t18 (10%)","12":"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).","13":null,"14":"Resite on clinical indication would allow one in two patients to have a single cannula per course of IV treatment, as opposed to one in five patients managed with routine resite; overall complication rates appear similar.","15":"There remained no effect when events were expressed per patient or per 1,000 IVD days.","16":"However, total complication rates per patient (to deliver the course of IV therapy) were not significantly different (P = 0.39) between clinically indicated (76\/185, 41%) and routine resite patients (64\/177, 36%).","17":"with significantly higher hospital costs per patient (P < 0.001).","18":"This review included six trials (n = 3,455) and reported no clinically important or statistically significant difference in catheter-related bloodstream infection or phlebitis between IVDs that were routinely resited (at 48-96 hours) or resited on clinical indication, yet there were significantly lower costs in the group resited on clinical indication","19":"with significantly higher hospital costs per patient (P < 0.001).","20":"IV therapy duration did not differ between groups (P = 0.22), but more (P = 0.004) IVDs were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5), with significantly higher hospital costs per patient (P < 0.001).","21":"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)","22":"Occlusion, n (%)\t5 (3%)\t4 (2%)\tRR 0.77 (0.21, 2.80), p = 0.75","23":"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).","24":"Occlusion, n (%)\t5 (3%)\t4 (2%)","25":"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).","26":"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (\u22121.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%)","27":"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).","28":"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (?1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%)","29":"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001)","30":"Hypoglycemia (symptoms and blood-glucose <3.0 mmol\/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).","31":"Hypoglycemia (symptoms and blood-glucose <3.0 mmol\/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).","32":"Hypoglycemia (symptoms and blood-glucose <3.0 mmol\/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively","33":"Hypoglycemia (symptoms and blood-glucose <3.0 mmol\/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).","34":"complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25\/48 (52%) in the HBOT group and 12\/42 (29%) in the placebo group (P = 0.03)","35":"In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up in 25\/48 (52%) in the HBOT group and 12\/42 (29%) in the placebo group (P = 0.03).","36":"n the per-protocol analysis, complete healing of the index ulcer occurred in 23\/38 (61%) in the HBOT group and 10\/37 (27%) in the placebo group (P = 0.009)","37":"complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25\/48 (52%) in the HBOT group and 12\/42 (29%) in the placebo group","38":"In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25\/48 (52%) in the HBOT group and 12\/42 (29%) in the placebo group (P = 0.03).","39":"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)","40":"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).","41":"5% difference in combined phlebitis and infiltration rates per patient (38% clinically indicated resite, 33% routine resite),","42":"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).","43":"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).","44":"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2\/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2\/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).","45":"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2\/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2\/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).","46":"The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system \ufffd?? on average 0.63 cm2\/per week. The smallest loss of ulceration area was observed in patients using compression stockings \ufffd?? on average 0.44 cm2\/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).","47":"We compared the dynamics of ulcer healing of patients treated with different types of compression therapy. The changes of ulceration area were statistically significant regardless of the type of compression therapy.","48":"The changes of ulceration area were statistically significant regardless of the type of compression therapy.","49":"The changes of ulceration area were statistically significant regardless of the type of compression therapy.","50":null,"51":"What is more, no statistically significant advantage of any of the applied types of compression therapy was found (Table II).","52":"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2\/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2\/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).","53":"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2\/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2\/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).","54":"complete healing was achieved in 10 (62.5%) ulcerations treated with the two-layer compression system and 9 (60%) ulcerations treated with the four-layer compression system.","55":"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).","56":"The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.","57":"Initial CEAP score (x \ufffd SD)\t11.9 \ufffd1.12\t11.2 \ufffd1.3\t12.6 \ufffd1.4\tp > 0.05","58":"Together with the progress in ulceration healing, statistically significant changes in CEAP scoring values (Table III) were observed. The difference in average CEAP C-6 score of all patients was 3.6 points and was statistically significant (p < 0.001). Also, in groups of patients divided according to the type of compression therapy, the differences in CEAP scoring values were statistically significant; they gained 3.5 points among patients who used compression stockings, 3.5 points among patients treated with the ProGuide system, and 4.3 points among patients treated with the Profore system. The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).","59":"Initial CEAP score (x \u00b1 SD)\t11.9 \u00b11.12\t11.2 \u00b11.3\t12.6 \u00b11.4","60":"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).","61":"Initial CEAP score (x \ufffd SD)\t11.9 \ufffd1.12\t11.2 \ufffd1.3\t12.6 \ufffd1.4\tp > 0.05","62":". Also, in groups of patients divided according to the type of compression therapy, the differences in CEAP scoring values were statistically significant; they gained 3.5 points among patients who used compression stockings, 3.5 points among patients treated with the ProGuide system, and 4.3 points among patients treated with the Profore system. The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).","63":"11.9 \u00b11.12\t11.2 \u00b11.3\t12.6 \u00b11.4\tp > 0.05","64":"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).","65":"Initial CEAP score (x \ufffd SD)\t11.9 \ufffd1.12\t11.2 \ufffd1.3\t12.6 \ufffd1.4\tp > 0.05","66":"The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.","67":"Together with the progress in ulceration healing, statistically significant changes in CEAP scoring values (Table III) were observed. The difference in average CEAP C-6 score of all patients was 3.6 points and was statistically significant (p < 0.001). Also, in groups of patients divided according to the type of compression therapy, the differences in CEAP scoring values were statistically significant; they gained 3.5 points among patients who used compression stockings, 3.5 points among patients treated with the ProGuide system, and 4.3 points among patients treated with the Profore system. The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).","68":"Initial CEAP score (x \u00b1 SD)\t11.9 \u00b11.12\t11.2 \u00b11.3\t12.6 \u00b11.4","69":"In our own research, the comparison of two pre-prepared Profore and ProGuide compression systems as well as elastic compression, that is to say, compression stockings, did not show statistically significant differences.","70":"greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2\/per week. The value of the same parameter in patients treated with the two-layer ProGuide compression system was 0.55 cm2\/per week and of those treated with compression stockings 0.44 cm2\/per week. Although the changes of ulceration area in each analysed group were statistically significant (p < 0.001), inter-group differences were not found (H = 4.45, p > 0.05).","71":"In the group of patients who used Maxis compression stockings complete healing was achieved in 8 (53.3%) ulcerations, in the groups of patients treated with layer compression systems, complete healing was achieved in 10 (62.5%) ulcerations treated with the two-layer compression system and 9 (60%) ulcerations treated with the four-layer compression system.","72":"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).","73":"However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed.","74":"However, greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2\/per week.","75":"However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed. The observed differences were statistically significant.","76":"greater dynamics of healing was observed in patients treated with the four-layer Profore system \ufffd?? the average loss of area during the whole 12-week observation period was 0.63 cm2\/per week.","77":"However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed.","78":"Table I\n\n\nComparable characteristics of patients treated with Maxis compression stockings and ProGuide two-layer and Profore four-layer compression systems","79":"Ulceration area [cm2] (x \ufffd SD)\t4.7 \ufffd4.18\t5.3 \ufffd3.93\t6.0 \ufffd3.98\tp > 0.05","80":"In the group of patients who used Maxis compression stockings complete healing was achieved in 8 (53.3%) ulcerations, in the groups of patients treated with layer compression systems, complete healing was achieved in 10 (62.5%) ulcerations treated with the two-layer compression system and 9 (60%) ulcerations treated with the four-layer compression system. The differences were statistically significant (p > 0.05).","81":"In our own research, the comparison of two pre-prepared Profore and ProGuide compression systems as well as elastic compression, that is to say, compression stockings, did not show statistically significant differences. However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed. The observed differences were statistically significant.","82":"The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system \ufffd?? on average 0.63 cm2\/per week. The smallest loss of ulceration area was observed in patients using compression stockings \ufffd?? on average 0.44 cm2\/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).","83":"no significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","84":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","85":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","86":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","87":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","88":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","89":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","90":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","91":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","92":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","93":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","94":". No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","95":"Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group.","96":"Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group.","97":"Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group","98":"Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group.","99":"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.","100":"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.","101":"Lack of an antibiotic effect on the gestational age at delivery may be due to the low prevalence of upper genital tract infection among unselected women in preterm labor, to advanced preterm labor unresponsive to antibiotic therapy, or to an inability of antibiotics given alone to inhibit the cytokine response.","102":"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.","103":"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.","104":"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.","105":null,"106":null,"107":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","108":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","109":"No significant difference was observed with respect to pregnancy or birth outcome across the groups","110":"Twice-weekly supplementation is as effective as daily supplementation, and may represent an acceptable compromise in iron supplementation regimens for nonanemic pregnant women.","111":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","112":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","113":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","114":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","115":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","116":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","117":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","118":"No significant difference was observed with respect to pregnancy or birth outcome across the groups","119":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","120":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","121":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","122":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","123":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","124":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","125":"No significant difference was observed with respect to pregnancy or birth outcome across the groups.","126":"An overall comparison of average birth parameters for the three treatment groups is summarized in Table 3. Infants born to women who were assigned to the different treatment groups showed no significant difference in average birth weight (P = 0.521). The difference in pregnancy termination week was insignificant across the randomization groups (P = 0.13), as was the incidence of cesarean section births, preterm delivery, and low birth weight across the groups (P = 0.31, 0.25, and 0.33, respectively). Two babies (one in Group A and one in Group C) were of low birth weight, and eight babies (Group A, n = 4; Group B, n = 3; Group C, n = 1) were delivered preterm.","127":"Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.","128":"No side effects were reported throughout the duration of the study.","129":"No side effects were reported throughout the duration of the study.","130":"No side effects were reported throughout the duration of the study.","131":"Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.","132":"No side effects were reported throughout the duration of the study.","133":"No side effects were reported throughout the duration of the study.","134":"No side effects were reported throughout the duration of the study.","135":"Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.","136":"No side effects were reported throughout the duration of the study.","137":"No side effects were reported throughout the duration of the study.","138":"No side effects were reported throughout the duration of the study.","139":"No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.","140":"No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.","141":null,"142":"No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.","143":"No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.","144":"No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.","145":null,"146":null,"147":"No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.","148":"No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.","149":null,"150":null,"151":"When comparing the final levels at 38 weeks, a significant difference was observed between Group B and the other two groups in this iron status indicator (P = 0.035). This difference was also of marginal clinical significance (19.9 \u03bcg\/L in Group B).","152":"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g\/dL, ferritin >19 ?g\/L).","153":"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g\/dL, ferritin >19 ?g\/L).","154":"here was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g\/dL, ferritin >19 ?g\/L).","155":"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.","156":"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.","157":"Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).","158":"Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).","159":"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.","160":". There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks","161":"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.","162":"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.","163":"Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).","164":"Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).","165":"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.","166":"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.","167":"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.","168":"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g\/dL, ferritin >19 ?g\/L).","169":"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g\/dL, ferritin >19 ?g\/L).","170":"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant","171":"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.","172":"Group B, on the other hand, achieved significantly lower ferritin levels compared with Group A and Group C at 38 weeks","173":null,"174":"Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).","175":"Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).","176":"The mean serum ferritin level increased significantly in Group C at 28 weeks? gestation (P = 0.03). When comparing the final levels at 38 weeks, a significant difference was observed between Group B and the other two groups in this iron status indicator (P = 0.035).","177":"Group B, on the other hand, achieved significantly lower ferritin levels compared with Group A and Group C at 38 weeks, but again this was not clinically significant.","178":"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant","179":"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.","180":"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g\/dL, ferritin >19 ?g\/L).","181":"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g\/dL, ferritin >19 ?g\/L).","182":"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g\/dL, ferritin >19 ?g\/L)","183":"The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.","184":"The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.","185":"The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.","186":"The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA","187":"The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.","188":"The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.","189":"The health assessment questionnaire disability index (HAQ-DI) was used to evaluate physical function.","190":"Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n ?=? 133), golimumab 100 mg injections plus placebo capsules (group 2, n ?=? 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n ?=? 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n ?=? 89).","191":"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.","192":"The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.","193":"The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.","194":null,"195":"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group,","196":"Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n ?=? 133), golimumab 100 mg injections plus placebo capsules (group 2, n ?=? 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n ?=? 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n ?=? 89)","197":"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group.","198":"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group,","199":"No difference in the improvement in median HAQ-DI score was observed between group 2 and group 1 (\u22120.13; p = 0.240). Overall, 38.6% of patients in group 1, 45.3% of patients in group 2 (p = 0.276), 68.2% of patients in group 3 (p<0.001) and 72.1% of patients in group 4 (p<0.001) achieved a reduction in HAQ-DI score of 0.25 or greater.","200":"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.","201":"Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n ?=? 133), golimumab 100 mg injections plus placebo capsules (group 2, n ?=? 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n ?=? 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n ?=? 89).","202":"No difference in the improvement in median HAQ-DI score was observed between group 2 and group 1 (?0.13; p?=?0.240).","203":"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240),","204":"At week 24, patients in the combined groups 3 and 4 also showed significantly greater improvement in the median HAQ-DI score (\u22120.44, p<0.001) compared with group 1 (\u22120.13), with improvements of \u22120.38 (p = 0.001) in group 3 and \u22120.50 (p<0.001) in group 4 (table 2).","205":"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.","206":"Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n ?=? 133), golimumab 100 mg injections plus placebo capsules (group 2, n ?=? 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n ?=? 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n ?=? 89).","207":"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.","208":"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively","209":"At week 24, patients in the combined groups 3 and 4 also showed significantly greater improvement in the median HAQ-DI score (\u22120.44, p<0.001) compared with group 1 (\u22120.13), with improvements of \u22120.38 (p = 0.001) in group 3 and \u22120.50 (p<0.001) in group 4 (table 2).","210":"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.","211":"Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n ?=? 133), golimumab 100 mg injections plus placebo capsules (group 2, n ?=? 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n ?=? 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n ?=? 89).","212":"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.","213":"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.","214":"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.","215":"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients","216":"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.","217":"Serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients, respectively.","218":"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3;","219":"<td align=\"left\" colspan=\"1\" rowspan=\"1\">Serious adverse events<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">5 (3.7%)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">0.09 (0.03 to 0.21)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">8 (6.0%)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">0.11 (0.06 to 0.19)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">9 (4.2%)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">0.08 (0.04 to 0.14)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">13 (12.4%)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">0.18 (0.10 to 0.30)<\/td>","220":"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.","221":"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.\n\n\n\n\n\n\n\n\nConclusion:","222":"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.","223":"<td align=\"left\" colspan=\"1\" rowspan=\"1\">Serious adverse events<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">5 (3.7%)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">0.09 (0.03 to 0.21)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">8 (6.0%)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">0.11 (0.06 to 0.19)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">9 (4.2%)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">0.08 (0.04 to 0.14)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">13 (12.4%)<\/td><td align=\"char\" colspan=\"1\" rowspan=\"1\">0.18 (0.10 to 0.30)<\/td>","224":"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3;","225":"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.","226":"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group.","227":"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.","228":"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.","229":"serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.","230":"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).","231":"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).","232":"<td colspan=\"6\"><hr><\/td>","233":"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).","234":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05)","235":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),","236":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05),","237":"<td colspan=\"6\"><hr><\/td>","238":null,"239":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),","240":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),","241":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),","242":"spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05)","243":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05)","244":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).","245":". With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05)","246":"there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05)","247":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).","248":"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).","249":"there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05)","250":"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).","251":"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05)","252":"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).","253":"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol","254":"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).","255":"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).","256":"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).","257":"<td colspan=\"6\"><hr><\/td>","258":"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05)","259":"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05) (Table 1).","260":"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05) (Table 1).","261":"Table 1\n\n\n\n\n\nObstetrical Outcomes","262":"Misoprostol n = 80 (%)\tDinoprostone n = 83 (%)\tStatistical significance","263":"Uterine Tachysystole\t10 (12.6%)\t3 (3.6%)\tp < 0.05","264":"uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group","265":"Uterine Hyperstimulation 2 (2.5%) 1 (1.2%) NS","266":"Uterine Hyperstimulation\t2 (2.5%)\t1 (1.2%)\tNS","267":"Table 1\n\n\n\n\n\nObstetrical Outcomes","268":"Misoprostol n = 80 (%)\tDinoprostone n = 83 (%)\tStatistical significance","269":"Uterine Hyperstimulation\t2 (2.5%)\t1 (1.2%)\tNS","270":"<td colspan=\"6\"><hr><\/td>","271":"Meconium stained AF 15 (18.8%) 7 (9.6%) NS","272":"Meconium stained AF\t15 (18.8%)\t7 (9.6%)\tNS","273":"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05) (Table 1).","274":"Misoprostol n = 80 (%)\tDinoprostone n = 83 (%)\tStatistical significance","275":"Meconium stained AF\t15 (18.8%)\t7 (9.6%)\tNS","276":"<td colspan=\"6\"><hr><\/td>","277":"Perinatal death 0 1(1.2%) NS","278":"Perinatal death\t0\t1(1.2%)\tNS","279":"Table 3\n\n\n\n\n\nNeonatal Outcomes","280":"Misoprostol n = 80 (%)\tDinoprostone n = 83 (%)\tStatistical significance","281":"Perinatal death\t0\t1(1.2%)\tNS","282":"Perinatal death 0 1(1.2%) NS ","283":"Neonatal resuscitation 9 (11.3%) 9 (10.8%) NS","284":"More neonates in the misoprostol group had first minute Apgar scores lower than 7 (12.6% vs. 6.1%, p > 0.05), or needed neonatal resuscitation (11.4% vs. 9.9%, p > 0.05) but none of the babies had birth asphyxia","285":"Neonatal resuscitation\t9 (11.3%)\t9 (10.8%)\tNS","286":"More neonates in the misoprostol group had first minute Apgar scores lower than 7 (12.6% vs. 6.1%, p > 0.05), or needed neonatal resuscitation (11.4% vs. 9.9%, p > 0.05) but none of the babies had birth asphyxia [23].","287":"Table 3\n\n\n\n\n\nNeonatal Outcomes","288":"Misoprostol n = 80 (%)\tDinoprostone n = 83 (%)\tStatistical significance","289":"Neonatal resuscitation\t9 (11.3%)\t9 (10.8%)\tNS","290":"Neonatal resuscitation\t9 (11.3%)\t9 (10.8%)","291":"Cord blood pH (arterial)1 7.28 \u00b1 0.05 7.27 \u00b1 0.05 NS","292":"The mean cord pH and the base deficit were comparable in the two groups.","293":"Table 3\n\n\n\n\n\nNeonatal Outcomes","294":"Misoprostol n = 80 (%)\tDinoprostone n = 83 (%)\tStatistical significance","295":"Cord blood pH (arterial)1\t7.28 \ufffd 0.05\t7.27 \ufffd 0.05\tNS","296":"Cord blood pH (arterial)1\t7.28 \u00b1 0.05\t7.27 \u00b1 0.05\tNS","297":"Hyperbilirubinemia 2 9 (11.3%) 5 (6.0%) NS","298":"Hyperbilirubinemia 2\t9 (11.3%)\t5 (6.0%)\tNS","299":"Table 3\n\n\n\n\n\nNeonatal Outcomes\n\n\nHyperbilirubinemia","300":"Misoprostol n = 80 (%)\tDinoprostone n = 83 (%)\tStatistical significance","301":"9 (11.3%)\t5 (6.0%)\tNS","302":"Hyperbilirubinemia 2\t9 (11.3%)\t5 (6.0%)\tNS","303":"Birth trauma 3 0 2 (2.5%) NS","304":"Birth trauma 3\t0\t2 (2.5%)\tNS","305":"Table 3\n\n\n\n\n\nNeonatal Outcomes","306":"Misoprostol n = 80 (%)\tDinoprostone n = 83 (%)\tStatistical significance","307":"Birth trauma 3\t0\t2 (2.5%)\tNS","308":"Birth trauma 3\t0\t2 (2.5%)\tNS","309":"There was no statistical difference in rates of vacuum-assisted delivery rate.","310":"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.","311":"There was no statistical difference in rates of vacuum-assisted delivery rate.","312":"There was no statistical difference in rates of vacuum-assisted delivery rate.","313":"Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.","314":"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.","315":"Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.","316":"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.","317":"Differences in the duration of the active-first and the second stages of labor were not statistically significant.","318":"Differences in the duration of the active-first and the second stages of labor were not statistically significant.","319":"Differences in the duration of the active-first and the second stages of labor were not statistically significant.","320":"Differences in the duration of the active-first and the second stages of labor were not statistically significant.","321":"Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation","322":"Oxytocin augmentation After initiation of Analgesia\t197(100)\t192(96)\tNS","323":"Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation","324":"Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation(Table 2).","325":"Table 2\n\n\n\n\n\nProgress of labor","326":"Labor progress\tEpidural N = 197\tMeperidine N = 198\tP value","327":"Oxytocin augmentation After initiation of Analgesia\t197(100)\t192(96)\tNS","328":"Oxytocin augmentation After initiation of Analgesia\t197(100)\t192(96)\tNS","329":"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 \u00b1 1.2 vs. intravenous meperidine, 9 \u00b1 1.3; P = 0.09)","330":"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 \ufffd 1.2 vs. intravenous meperidine, 9 \ufffd 1.3; P = 0.09).","331":null,"332":"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 \u00b1 1.2 vs. intravenous meperidine, 9 \u00b1 1.3; P = 0.09).","333":"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 \u00b1 3 vs. meperidine, 6 \u00b1 4; P < 0.0001) and second stage (epidural, 4 \u00b1 3 vs. meperidine, 8 \u00b1 2; P < 0.0001) of labor","334":"Active phase of first Stage of labor (h)\t2.49 \ufffd 1.40\t2.40 \ufffd 1.55\tNS","335":"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 \ufffd 3 vs. meperidine, 6 \ufffd 4; P < 0.0001) and second stage (epidural, 4 \ufffd 3 vs. meperidine, 8 \ufffd 2; P < 0.0001) of labor.","336":"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 \u00b1 3 vs. meperidine, 6 \u00b1 4; P < 0.0001) and second stage (epidural, 4 \u00b1 3 vs. meperidine, 8 \u00b1 2; P < 0.0001) of labor.","337":"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 \u00b1 3 vs. meperidine, 6 \u00b1 4; P < 0.0001) and second stage (epidural, 4 \u00b1 3 vs. meperidine, 8 \u00b1 2; P < 0.0001) of labor","338":"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 \ufffd 3 vs. meperidine, 6 \ufffd 4; P < 0.0001) and second stage (epidural, 4 \ufffd 3 vs. meperidine, 8 \ufffd 2; P < 0.0001) of labor.","339":"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 \ufffd 3 vs. meperidine, 6 \ufffd 4; P < 0.0001) and second stage (epidural, 4 \ufffd 3 vs. meperidine, 8 \ufffd 2; P < 0.0001) of labor.","340":"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 \u00b1 3 vs. meperidine, 6 \u00b1 4; P < 0.0001) and second stage (epidural, 4 \u00b1 3 vs. meperidine, 8 \u00b1 2; P < 0.0001) of labor.","341":"Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001)","342":"Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001).","343":"Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001).","344":"Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001)","345":"There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%)","346":"There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%).","347":"There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%).","348":"There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%).","349":"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.","350":"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.","351":"In summary, lumbar epidural analgesia with 1% lidocaine does not prolong the active-first and second stages of labor and does not increase the vacuum-assisted or cesarean delivery rate, when compared with intravenous meperidine. Epidural labor analgesia can be delivered, even in communities with significant economic, cultural and religious barriers to this technique. The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.","352":"As shown in table 4, infant outcome showed no evidence that the type of analgesia had any adverse effects on neonatal Apgar scores.","353":"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups. Differences in the duration of the active-first and the second stages of labor were not statistically significant. The number of newborns with 1-min and 5-min Apgar scores less than 7, did not differ significantly between both analgesia groups.","354":"here was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups. Differences in the duration of the active-first and the second stages of labor were not statistically significant. The number of newborns with 1-min and 5-min Apgar scores less than 7, did not differ significantly between both analgesia groups","355":"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.","356":"Women in both groups were similar in both obstetric and demographic characteristics","357":"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.","358":"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.","359":"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries","360":"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.","361":"As shown in table 4, infant outcome showed no evidence that the type of analgesia had any adverse effects on neonatal Apgar scores.","362":"The number of newborns with 1-min and 5-min Apgar scores less than 7, did not differ significantly between both analgesia groups.","363":"The number of newborns with 1-min and 5-min Apgar scores less than 7, did not differ significantly between both analgesia groups.","364":"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9\u201312: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7\u20139.4; p < .0001) and through 24 weeks follow-up (Weeks 9\u201324: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6\u20137.5; p < .0001)","365":"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001)","366":"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001) and through 24 weeks follow-up (Weeks 9?24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6?7.5; p < .0001).","367":"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9\ufffd??12: 53.1% vs. 19.3%;","368":"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9\u201312: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7\u20139.4; p < .0001) and through 24 weeks follow-up (Weeks 9\u201324: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6\u20137.5; p < .0001)","369":"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001) and through 24 weeks follow-up (Weeks 9?24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6?7.5; p < .0001).","370":"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001) and through 24 weeks follow-up (Weeks 9?24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6?7.5; p < .0001).","371":"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9\ufffd??12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7\ufffd??9.4; p < .0001) and through 24 weeks follow-up (Weeks 9\ufffd??24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6\ufffd??7.5; p < .0001).","372":"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062). ","373":"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).","374":"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).","375":"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).","376":"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).","377":"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).","378":"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).","379":"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074)","380":"Improvements in A1C were \u22121.46 \u00b1 1.09% for glargine and \u22121.54 \u00b1 1.11% for detemir (P = 0.149)","381":"Improvements in A1C were ?1.46 \ufffd 1.09% for glargine and ?1.54 \ufffd 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).","382":"Improvements in A1C were ?1.46 \ufffd 1.09% for glargine and ?1.54 \ufffd 1.11% for detemir (P = 0.149),","383":"Improvements in A1C were ?1.46 \u00b1 1.09% for glargine and ?1.54 \u00b1 1.11% for detemir (P = 0.149)","384":"with similar proportions of patients achieving A1C <7% (P = 0.254)","385":"The proportions of patients achieving A1C <7% were also similar (44.1 and 47.8%, respectively, P = 0.254), but significantly fewer glargine- than detemir-treated patients reached A1C <6.5% (16.5 and 22.7%, respectively, P = 0.017).","386":"Improvements in A1C were ?1.46 \ufffd 1.09% for glargine and ?1.54 \ufffd 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).","387":"27.5 and 25.6% of patients reached the primary outcome with glargine and detemir, respectively, demonstrating the noninferiority of glargine. Improvements in A1C were ?1.46 \u00b1 1.09% for glargine and ?1.54 \u00b1 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254)","388":"more detemir-treated patients reaching A1C <6.5% (P = 0.017)","389":"Improvements in A1C were ?1.46 \ufffd 1.09% for glargine and ?1.54 \ufffd 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).","390":"Improvements in A1C were ?1.46 \ufffd 1.09% for glargine and ?1.54 \ufffd 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).","391":"more detemir-treated patients reaching A1C <6.5% (P = 0.017).","392":"Hypoglycemia risk was similar.","393":"Hypoglycemia risk was similar.","394":"Hypoglycemia risk was similar.","395":"Hypoglycemia risk was similar.","396":"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).","397":"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).","398":"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).","399":"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).","400":"Insulin doses, however, were significantly lower for glargine: 43.5 \u00b1 29.0 versus 76.5 \u00b1 50.5 units\/day (P < 0.001) (Fig. 1B)","401":"Insulin doses, however, were significantly lower for glargine: 43.5 \ufffd 29.0 versus 76.5 \ufffd 50.5 units\/day (P < 0.001)","402":"Moreover, trial data suggest that, although insulin doses are indeed higher in patients using detemir twice- versus once-daily, once-daily detemir doses are still higher than once-daily NPH and glargine doses (3,10,11). At present there is no clear explanation for the increased dose requirements for detemir","403":"Insulin doses, however, were significantly lower for glargine: 43.5 \ufffd 29.0 versus 76.5 \ufffd 50.5 units\/day (P < 0.001) (Fig. 1B)","404":"nsulin doses, however, were significantly lower for glargine: 43.5 \u00b1 29.0 versus 76.5 \u00b1 50.5 units\/day","405":"Detemir-treated patients had less weight gain and more often achieved A1C <6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.","406":"Detemir-treated patients had less weight gain and more often achieved A1C <6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.","407":null,"408":"our study confirms the higher weight gain, lower daily insulin doses, and fewer drop-outs (because of adverse events) for glargine versus detemir,","409":"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).","410":"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).","411":"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).","412":"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).","413":"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).","414":"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).","415":"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53)","416":"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).","417":"There were no local infections or IVD-related bloodstream infections in either group. ","418":"There were no local infections or IVD-related bloodstream infections in either group.","419":"There were no local infections or IVD-related bloodstream infections in either group.","420":"No cases of local infection or IVD-related bloodstream infection occurred in either group.","421":"IV therapy duration did not differ between groups (P = 0.22)","422":"IV therapy duration did not differ between groups (P = 0.22),","423":"IV therapy duration did not differ between groups (P = 0.22), but more (P = 0.004) IVDs were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5), with significantly higher hospital costs per patient (P < 0.001).","424":"IV therapy duration did not differ between groups (P = 0.22),","425":"but more (P = 0.004) IVDs were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5)","426":"The overall number of IVDs per patient was significantly less (P = 0.004) for those replaced on clinical indication (mean 1.5, SD 0.8, median 1, quartiles 1 and 2) than for those routinely replaced (mean 1.8, SD 1.1, median 1, quartiles 1 and 2)","427":"IV therapy duration did not differ between groups (P = 0.22), but more (P = 0.004) IVDs were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5), with significantly higher hospital costs per patient (P < 0.001).","428":"A total of 22% of patients in the routinely replaced group had three or more IVDs compared with 9% in the clinical indication group."},"Label Code":{"0":1,"1":1,"2":1,"3":1,"4":1,"5":1,"6":1,"7":1,"8":1,"9":0,"10":0,"11":0,"12":0,"13":0,"14":0,"15":0,"16":0,"17":1,"18":1,"19":1,"20":1,"21":0,"22":0,"23":0,"24":0,"25":0,"26":-1,"27":-1,"28":-1,"29":-1,"30":0,"31":0,"32":0,"33":0,"34":1,"35":1,"36":1,"37":1,"38":1,"39":0,"40":0,"41":0,"42":0,"43":0,"44":0,"45":0,"46":0,"47":1,"48":1,"49":1,"50":3,"51":0,"52":0,"53":0,"54":0,"55":0,"56":0,"57":0,"58":0,"59":1,"60":0,"61":0,"62":0,"63":0,"64":0,"65":0,"66":0,"67":0,"68":0,"69":0,"70":0,"71":0,"72":0,"73":1,"74":1,"75":1,"76":1,"77":1,"78":0,"79":0,"80":0,"81":1,"82":0,"83":0,"84":0,"85":0,"86":0,"87":0,"88":0,"89":0,"90":0,"91":0,"92":0,"93":0,"94":0,"95":-1,"96":-1,"97":-1,"98":-1,"99":0,"100":0,"101":0,"102":0,"103":0,"104":0,"105":3,"106":3,"107":0,"108":0,"109":0,"110":0,"111":0,"112":0,"113":0,"114":0,"115":0,"116":0,"117":0,"118":0,"119":0,"120":0,"121":0,"122":0,"123":0,"124":0,"125":0,"126":0,"127":0,"128":0,"129":0,"130":0,"131":0,"132":0,"133":0,"134":0,"135":0,"136":0,"137":0,"138":0,"139":0,"140":0,"141":3,"142":0,"143":0,"144":0,"145":3,"146":3,"147":0,"148":0,"149":3,"150":3,"151":-1,"152":0,"153":0,"154":0,"155":1,"156":1,"157":1,"158":1,"159":1,"160":1,"161":1,"162":1,"163":1,"164":1,"165":1,"166":1,"167":0,"168":0,"169":0,"170":0,"171":0,"172":0,"173":0,"174":0,"175":0,"176":0,"177":0,"178":0,"179":0,"180":0,"181":0,"182":0,"183":-1,"184":-1,"185":-1,"186":-1,"187":1,"188":1,"189":1,"190":1,"191":1,"192":1,"193":1,"194":0,"195":0,"196":0,"197":0,"198":0,"199":0,"200":0,"201":0,"202":0,"203":0,"204":1,"205":1,"206":1,"207":1,"208":1,"209":1,"210":1,"211":1,"212":1,"213":1,"214":1,"215":0,"216":0,"217":1,"218":1,"219":1,"220":1,"221":0,"222":0,"223":1,"224":1,"225":1,"226":0,"227":0,"228":0,"229":0,"230":-1,"231":-1,"232":-1,"233":-1,"234":1,"235":1,"236":1,"237":1,"238":1,"239":1,"240":1,"241":1,"242":1,"243":1,"244":1,"245":1,"246":-1,"247":-1,"248":-1,"249":-1,"250":0,"251":0,"252":0,"253":0,"254":0,"255":0,"256":0,"257":0,"258":1,"259":1,"260":1,"261":1,"262":1,"263":1,"264":1,"265":0,"266":0,"267":0,"268":0,"269":0,"270":0,"271":0,"272":0,"273":0,"274":0,"275":0,"276":0,"277":0,"278":0,"279":0,"280":0,"281":0,"282":0,"283":0,"284":0,"285":0,"286":0,"287":0,"288":0,"289":0,"290":0,"291":0,"292":0,"293":0,"294":0,"295":0,"296":0,"297":0,"298":0,"299":0,"300":0,"301":0,"302":0,"303":0,"304":0,"305":0,"306":0,"307":0,"308":0,"309":0,"310":0,"311":0,"312":0,"313":0,"314":0,"315":0,"316":0,"317":0,"318":0,"319":0,"320":0,"321":0,"322":0,"323":0,"324":0,"325":0,"326":0,"327":0,"328":0,"329":0,"330":0,"331":3,"332":0,"333":-1,"334":0,"335":-1,"336":-1,"337":-1,"338":-1,"339":-1,"340":1,"341":1,"342":1,"343":1,"344":1,"345":0,"346":0,"347":0,"348":0,"349":0,"350":0,"351":0,"352":0,"353":0,"354":0,"355":0,"356":0,"357":0,"358":0,"359":0,"360":0,"361":0,"362":0,"363":0,"364":1,"365":1,"366":1,"367":1,"368":1,"369":1,"370":1,"371":1,"372":0,"373":0,"374":0,"375":0,"376":-1,"377":1,"378":-1,"379":1,"380":0,"381":0,"382":0,"383":0,"384":0,"385":0,"386":0,"387":0,"388":1,"389":1,"390":1,"391":1,"392":0,"393":0,"394":0,"395":0,"396":1,"397":1,"398":1,"399":1,"400":-1,"401":-1,"402":-1,"403":-1,"404":-1,"405":-1,"406":-1,"407":3,"408":1,"409":0,"410":0,"411":0,"412":0,"413":0,"414":0,"415":0,"416":0,"417":0,"418":0,"419":0,"420":0,"421":0,"422":0,"423":0,"424":0,"425":1,"426":1,"427":1,"428":1},"In Abstract":{"0":true,"1":true,"2":true,"3":true,"4":true,"5":true,"6":true,"7":true,"8":true,"9":true,"10":true,"11":true,"12":true,"13":true,"14":true,"15":true,"16":true,"17":true,"18":true,"19":true,"20":true,"21":true,"22":true,"23":true,"24":true,"25":true,"26":true,"27":false,"28":false,"29":false,"30":true,"31":true,"32":true,"33":true,"34":true,"35":true,"36":true,"37":true,"38":true,"39":true,"40":true,"41":true,"42":true,"43":true,"44":true,"45":true,"46":true,"47":true,"48":false,"49":false,"50":false,"51":true,"52":true,"53":true,"54":true,"55":true,"56":true,"57":true,"58":true,"59":true,"60":true,"61":true,"62":true,"63":true,"64":true,"65":true,"66":true,"67":true,"68":true,"69":true,"70":false,"71":false,"72":false,"73":true,"74":true,"75":true,"76":true,"77":true,"78":false,"79":false,"80":false,"81":false,"82":false,"83":true,"84":true,"85":true,"86":true,"87":true,"88":true,"89":true,"90":true,"91":true,"92":true,"93":true,"94":true,"95":true,"96":true,"97":true,"98":true,"99":true,"100":true,"101":true,"102":true,"103":true,"104":true,"105":true,"106":true,"107":true,"108":true,"109":true,"110":true,"111":true,"112":true,"113":true,"114":true,"115":true,"116":true,"117":true,"118":true,"119":true,"120":true,"121":true,"122":true,"123":true,"124":true,"125":true,"126":true,"127":true,"128":false,"129":false,"130":false,"131":true,"132":false,"133":false,"134":false,"135":true,"136":false,"137":false,"138":false,"139":true,"140":false,"141":false,"142":false,"143":true,"144":false,"145":false,"146":false,"147":true,"148":false,"149":false,"150":false,"151":true,"152":true,"153":true,"154":true,"155":true,"156":true,"157":true,"158":true,"159":true,"160":true,"161":true,"162":true,"163":true,"164":true,"165":true,"166":true,"167":true,"168":true,"169":true,"170":true,"171":true,"172":true,"173":true,"174":true,"175":true,"176":true,"177":true,"178":true,"179":true,"180":true,"181":true,"182":true,"183":true,"184":true,"185":true,"186":true,"187":true,"188":true,"189":true,"190":true,"191":true,"192":true,"193":true,"194":true,"195":true,"196":true,"197":true,"198":true,"199":true,"200":true,"201":true,"202":true,"203":true,"204":true,"205":true,"206":true,"207":true,"208":true,"209":true,"210":true,"211":true,"212":true,"213":true,"214":true,"215":false,"216":false,"217":false,"218":false,"219":false,"220":true,"221":false,"222":false,"223":false,"224":false,"225":true,"226":false,"227":false,"228":false,"229":false,"230":true,"231":true,"232":true,"233":true,"234":true,"235":true,"236":true,"237":true,"238":true,"239":true,"240":true,"241":true,"242":true,"243":true,"244":true,"245":true,"246":true,"247":true,"248":true,"249":true,"250":true,"251":true,"252":true,"253":true,"254":true,"255":true,"256":true,"257":true,"258":false,"259":true,"260":true,"261":true,"262":true,"263":true,"264":true,"265":false,"266":false,"267":false,"268":false,"269":false,"270":false,"271":true,"272":false,"273":false,"274":false,"275":false,"276":false,"277":true,"278":false,"279":false,"280":false,"281":false,"282":false,"283":true,"284":true,"285":true,"286":true,"287":true,"288":true,"289":true,"290":true,"291":true,"292":true,"293":true,"294":true,"295":true,"296":true,"297":true,"298":true,"299":true,"300":true,"301":true,"302":true,"303":true,"304":true,"305":true,"306":true,"307":true,"308":true,"309":true,"310":true,"311":true,"312":true,"313":true,"314":true,"315":true,"316":true,"317":true,"318":true,"319":true,"320":true,"321":true,"322":true,"323":true,"324":true,"325":true,"326":true,"327":true,"328":true,"329":true,"330":false,"331":false,"332":false,"333":true,"334":true,"335":true,"336":true,"337":true,"338":false,"339":false,"340":false,"341":true,"342":true,"343":true,"344":true,"345":true,"346":true,"347":true,"348":true,"349":true,"350":true,"351":true,"352":true,"353":true,"354":true,"355":true,"356":true,"357":true,"358":true,"359":true,"360":true,"361":true,"362":true,"363":true,"364":true,"365":true,"366":true,"367":true,"368":true,"369":true,"370":true,"371":true,"372":true,"373":false,"374":false,"375":false,"376":true,"377":false,"378":false,"379":false,"380":true,"381":true,"382":true,"383":true,"384":true,"385":true,"386":true,"387":true,"388":true,"389":true,"390":true,"391":true,"392":true,"393":true,"394":true,"395":true,"396":true,"397":true,"398":true,"399":true,"400":true,"401":true,"402":true,"403":true,"404":true,"405":true,"406":false,"407":false,"408":false,"409":true,"410":true,"411":true,"412":true,"413":true,"414":true,"415":true,"416":true,"417":true,"418":true,"419":true,"420":true,"421":true,"422":true,"423":true,"424":true,"425":true,"426":true,"427":true,"428":true},"Evidence Start":{"0":17992,"1":17992,"2":17992,"3":17992,"4":24238,"5":24238,"6":24482,"7":24238,"8":24238,"9":23690,"10":1548,"11":21729,"12":23690,"13":-1,"14":1922,"15":28023,"16":21111,"17":1833,"18":27594,"19":1833,"20":1634,"21":23690,"22":21863,"23":23690,"24":24173,"25":23690,"26":842,"27":13367,"28":842,"29":13360,"30":15367,"31":15367,"32":15367,"33":15367,"34":1063,"35":12944,"36":13149,"37":1063,"38":1027,"39":23690,"40":23690,"41":8133,"42":23690,"43":1366,"44":874,"45":874,"46":1072,"47":11141,"48":11248,"49":11248,"50":-1,"51":12678,"52":874,"53":874,"54":12988,"55":15434,"56":10326,"57":11048,"58":14829,"59":12707,"60":15434,"61":11048,"62":15087,"63":11076,"64":15434,"65":11048,"66":10326,"67":14829,"68":11048,"69":17825,"70":12132,"71":12804,"72":1366,"73":18045,"74":12123,"75":18045,"76":12123,"77":18045,"78":12204,"79":12635,"80":14462,"81":17824,"82":1080,"83":1007,"84":1007,"85":1007,"86":1007,"87":1007,"88":1007,"89":1007,"90":1007,"91":1007,"92":1007,"93":1007,"94":1007,"95":1148,"96":1148,"97":1148,"98":1148,"99":741,"100":741,"101":1573,"102":1007,"103":741,"104":741,"105":-1,"106":-1,"107":1417,"108":1417,"109":1417,"110":1716,"111":1417,"112":1417,"113":1417,"114":1417,"115":1417,"116":1417,"117":1417,"118":1417,"119":1417,"120":1417,"121":1417,"122":1417,"123":1417,"124":1417,"125":1417,"126":17023,"127":17754,"128":17849,"129":17849,"130":17849,"131":17754,"132":17849,"133":17849,"134":17849,"135":17754,"136":17849,"137":17849,"138":17849,"139":16386,"140":16386,"141":-1,"142":16386,"143":16386,"144":16386,"145":-1,"146":-1,"147":16386,"148":16386,"149":-1,"150":-1,"151":16753,"152":1115,"153":1115,"154":1115,"155":20622,"156":1337,"157":571,"158":571,"159":1337,"160":1336,"161":20622,"162":1337,"163":571,"164":571,"165":1337,"166":1337,"167":20622,"168":1107,"169":1107,"170":1107,"171":20622,"172":20890,"173":172,"174":571,"175":571,"176":16653,"177":20890,"178":1107,"179":20622,"180":1107,"181":1107,"182":1097,"183":1790,"184":1790,"185":1790,"186":1789,"187":1790,"188":1790,"189":9524,"190":387,"191":1412,"192":1790,"193":1790,"194":4953,"195":1097,"196":387,"197":1096,"198":1097,"199":19267,"200":1412,"201":387,"202":19267,"203":1412,"204":19002,"205":1087,"206":387,"207":1412,"208":1412,"209":19002,"210":1087,"211":387,"212":1412,"213":1412,"214":23099,"215":1561,"216":23099,"217":21839,"218":23100,"219":15284,"220":23099,"221":1560,"222":23099,"223":15284,"224":23100,"225":23099,"226":1105,"227":1562,"228":23099,"229":1626,"230":889,"231":889,"232":205,"233":889,"234":1033,"235":1033,"236":1033,"237":205,"238":562,"239":1033,"240":1033,"241":1033,"242":1158,"243":1033,"244":1033,"245":1032,"246":1249,"247":1033,"248":1033,"249":1249,"250":1390,"251":1390,"252":1390,"253":1390,"254":1390,"255":1390,"256":1390,"257":205,"258":11229,"259":11229,"260":11229,"261":11434,"262":11465,"263":12032,"264":11238,"265":12082,"266":12082,"267":11434,"268":11465,"269":12079,"270":205,"271":11953,"272":11953,"273":11229,"274":11465,"275":11950,"276":205,"277":14203,"278":14203,"279":14058,"280":11465,"281":14200,"282":14203,"283":14232,"284":13423,"285":14229,"286":13422,"287":14058,"288":11465,"289":14229,"290":14232,"291":14427,"292":13640,"293":14058,"294":11465,"295":14425,"296":14427,"297":14607,"298":14607,"299":14048,"300":11465,"301":14627,"302":14607,"303":14651,"304":14651,"305":14058,"306":11465,"307":14648,"308":14651,"309":1120,"310":1120,"311":1120,"312":1120,"313":1199,"314":1120,"315":1199,"316":1120,"317":1320,"318":1320,"319":1320,"320":1320,"321":9037,"322":9736,"323":9038,"324":9038,"325":9528,"326":9568,"327":9736,"328":9736,"329":11192,"330":11192,"331":-1,"332":11192,"333":11350,"334":11270,"335":11350,"336":11350,"337":11350,"338":11350,"339":11350,"340":11350,"341":11569,"342":11569,"343":11569,"344":11569,"345":11740,"346":11740,"347":11740,"348":11740,"349":21897,"350":21897,"351":21521,"352":10427,"353":1120,"354":1120,"355":21897,"356":8926,"357":21898,"358":1120,"359":1120,"360":21897,"361":10426,"362":1435,"363":1435,"364":1143,"365":1143,"366":1143,"367":1142,"368":1143,"369":1143,"370":1143,"371":1134,"372":17773,"373":17773,"374":17773,"375":17773,"376":17922,"377":17922,"378":17922,"379":19618,"380":833,"381":833,"382":833,"383":833,"384":928,"385":4772,"386":833,"387":691,"388":999,"389":833,"390":833,"391":999,"392":1061,"393":1061,"394":1061,"395":1061,"396":1092,"397":1092,"398":1092,"399":1092,"400":5584,"401":5584,"402":6798,"403":5584,"404":5584,"405":8422,"406":8422,"407":-1,"408":7347,"409":1288,"410":1288,"411":1288,"412":1288,"413":1449,"414":1449,"415":1449,"416":1449,"417":1548,"418":1548,"419":1548,"420":23869,"421":1634,"422":1634,"423":1634,"424":1634,"425":1696,"426":24648,"427":1634,"428":24895},"Evidence End":{"0":18092,"1":18094,"2":18094,"3":18094,"4":24481,"5":24479,"6":24647,"7":24481,"8":24481,"9":23868,"10":1633,"11":21762,"12":23870,"13":0,"14":2143,"15":28110,"16":21325,"17":1898,"18":27949,"19":1898,"20":1897,"21":23868,"22":21925,"23":23867,"24":24204,"25":23870,"26":1000,"27":13564,"28":1001,"29":13923,"30":15536,"31":15536,"32":15528,"33":15536,"34":1228,"35":13147,"36":13305,"37":1218,"38":1228,"39":23868,"40":23870,"41":8259,"42":23870,"43":1476,"44":1475,"45":1475,"46":1475,"47":11358,"48":11358,"49":11358,"50":0,"51":12805,"52":1475,"53":1475,"54":13163,"55":15572,"56":10473,"57":11117,"58":15564,"59":12767,"60":15572,"61":11117,"62":15570,"63":11117,"64":15572,"65":11117,"66":10473,"67":15564,"68":11107,"69":18046,"70":12676,"71":13163,"72":1476,"73":18191,"74":12321,"75":18248,"76":12321,"77":18191,"78":12357,"79":12704,"80":14878,"81":18248,"82":1485,"83":1138,"84":1138,"85":1138,"86":1138,"87":1138,"88":1138,"89":1138,"90":1138,"91":1138,"92":1138,"93":1138,"94":1138,"95":1287,"96":1287,"97":1287,"98":1287,"99":930,"100":930,"101":1891,"102":1138,"103":930,"104":930,"105":0,"106":0,"107":1517,"108":1517,"109":1517,"110":1892,"111":1517,"112":1517,"113":1517,"114":1517,"115":1517,"116":1517,"117":1517,"118":1517,"119":1517,"120":1517,"121":1517,"122":1517,"123":1517,"124":1517,"125":1517,"126":17700,"127":17918,"128":17918,"129":17918,"130":17918,"131":17918,"132":17918,"133":17918,"134":17918,"135":17918,"136":17918,"137":17918,"138":17918,"139":16487,"140":16487,"141":0,"142":16487,"143":16487,"144":16487,"145":0,"146":0,"147":16487,"148":16487,"149":0,"150":0,"151":17003,"152":1345,"153":1345,"154":1345,"155":20890,"156":1416,"157":808,"158":808,"159":1416,"160":1416,"161":20890,"162":1416,"163":808,"164":808,"165":1416,"166":1416,"167":20890,"168":1336,"169":1336,"170":1295,"171":20890,"172":21008,"173":182,"174":808,"175":808,"176":16919,"177":21056,"178":1295,"179":20890,"180":1336,"181":1336,"182":1333,"183":1970,"184":1970,"185":1970,"186":1936,"187":1970,"188":1970,"189":9625,"190":748,"191":1552,"192":1970,"193":1970,"194":4963,"195":1277,"196":747,"197":1411,"198":1277,"199":19605,"200":1552,"201":748,"202":19383,"203":1503,"204":19267,"205":1552,"206":748,"207":1552,"208":1552,"209":19267,"210":1552,"211":748,"212":1552,"213":1552,"214":23275,"215":1700,"216":23275,"217":21926,"218":23227,"219":15835,"220":23275,"221":1797,"222":23275,"223":15835,"224":23227,"225":23275,"226":1419,"227":1774,"228":23275,"229":1775,"230":1031,"231":1031,"232":242,"233":1031,"234":1156,"235":1157,"236":1248,"237":242,"238":571,"239":1157,"240":1157,"241":1157,"242":1247,"243":1322,"244":1389,"245":1247,"246":1388,"247":1389,"248":1389,"249":1322,"250":1625,"251":1522,"252":1625,"253":1496,"254":1625,"255":1625,"256":1625,"257":242,"258":11424,"259":11434,"260":11432,"261":11465,"262":11537,"263":12082,"264":11364,"265":12129,"266":12129,"267":11465,"268":11537,"269":12124,"270":242,"271":11997,"272":11997,"273":11432,"274":11537,"275":11992,"276":242,"277":14233,"278":14233,"279":14086,"280":11537,"281":14228,"282":14233,"283":14280,"284":13635,"285":14274,"286":13638,"287":14086,"288":11537,"289":14274,"290":14274,"291":14478,"292":13714,"293":14086,"294":11537,"295":14478,"296":14478,"297":14648,"298":14648,"299":14100,"300":11537,"301":14647,"302":14648,"303":14678,"304":14678,"305":14086,"306":11537,"307":14677,"308":14678,"309":1198,"310":1319,"311":1198,"312":1198,"313":1319,"314":1319,"315":1319,"316":1319,"317":1434,"318":1434,"319":1434,"320":1434,"321":9224,"322":9807,"323":9224,"324":9234,"325":9568,"326":9627,"327":9807,"328":9807,"329":11349,"330":11348,"331":0,"332":11348,"333":11568,"334":11339,"335":11568,"336":11568,"337":11568,"338":11568,"339":11568,"340":11568,"341":11739,"342":11741,"343":11741,"344":11739,"345":11871,"346":11873,"347":11873,"348":11873,"349":22098,"350":22098,"351":22096,"352":10558,"353":1564,"354":1564,"355":22098,"356":9010,"357":22097,"358":1319,"359":1219,"360":22098,"361":10559,"362":1564,"363":1564,"364":1417,"365":1320,"366":1418,"367":1271,"368":1417,"369":1418,"370":1418,"371":1417,"372":17922,"373":17923,"374":17923,"375":17923,"376":18108,"377":18108,"378":18108,"379":19741,"380":926,"381":1060,"382":927,"383":926,"384":994,"385":5004,"386":1060,"387":994,"388":1059,"389":1060,"390":1060,"391":1060,"392":1091,"393":1091,"394":1091,"395":1091,"396":1161,"397":1161,"398":1161,"399":1161,"400":5710,"401":5699,"402":7108,"403":5710,"404":5688,"405":8584,"406":8584,"407":0,"408":7494,"409":1447,"410":1447,"411":1447,"412":1447,"413":1547,"414":1547,"415":1546,"416":1547,"417":1634,"418":1633,"419":1633,"420":23961,"421":1694,"422":1695,"423":1897,"424":1695,"425":1831,"426":24894,"427":1897,"428":25029}}